These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 21360486)
61. Development of recurrent pseudoseptic arthritis in a patient with rheumatoid arthritis receiving TNF-alpha blocker. Korkmaz C; Kaşifoğlu T Joint Bone Spine; 2006 Dec; 73(6):767-8. PubMed ID: 17126056 [No Abstract] [Full Text] [Related]
62. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Marotte H; Arnaud B; Diasparra J; Zrioual S; Miossec P Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841 [TBL] [Abstract][Full Text] [Related]
63. [Rheumatoid arthritis: determination of the current status]. Michel BA Z Rheumatol; 2001 Oct; 60(5):307-8. PubMed ID: 11759229 [No Abstract] [Full Text] [Related]
64. Mortality rates among patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: comment on the article by Simard et al. Moulis G; Sommet A; Lapeyre-Mestre M Arthritis Rheum; 2013 Jun; 65(6):1670-1. PubMed ID: 23508973 [No Abstract] [Full Text] [Related]
65. Tumor necrosis factor inhibitor therapy for rheumatoid arthritis. Naguwa SM Ann N Y Acad Sci; 2005 Jun; 1051():709-15. PubMed ID: 16127011 [TBL] [Abstract][Full Text] [Related]
66. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis? Kavanaugh A Nat Clin Pract Rheumatol; 2006 Jul; 2(7):346-7. PubMed ID: 16932716 [No Abstract] [Full Text] [Related]
67. Effects of tumor necrosis factor-alpha inhibitors on lung lesions with rheumatoid arthritis. Inoue K; Takano H; Yanagisawa R; Yoshikawa T Chest; 2003 Jul; 124(1):413-4; author reply 414. PubMed ID: 12853558 [No Abstract] [Full Text] [Related]
68. [TNF-alpha blocker in rheumatoid arthritis. Who should be treated with the new substances?]. MMW Fortschr Med; 2000 Nov; 142(44):6. PubMed ID: 11107796 [No Abstract] [Full Text] [Related]
69. An alternative, autonomic rationale for decreased risk of myocardial infarction in patients with rheumatoid arthritis responsive to anti-tumor necrosis factor therapy: comment on the article by Dixon et al. Holman AJ Arthritis Rheum; 2008 Jun; 58(6):1886; author reply 1886. PubMed ID: 18512805 [No Abstract] [Full Text] [Related]
70. Active tuberculosis in a patient with rheumatoid arthritis treated with tumor necrosis factor-alpha inhibitor. Fuchs I; Abu-Shakra M; Gelfer E; Smoliakov A; Ben-Haroch D; Horowitz J; Avnon LS Isr Med Assoc J; 2010 Sep; 12(9):579-81. PubMed ID: 21287806 [No Abstract] [Full Text] [Related]
71. Rheumatoid arthritis: anticytokine therapies on the horizon. Koopman WJ; Moreland LW Ann Intern Med; 1998 Feb; 128(3):231-3. PubMed ID: 9454532 [No Abstract] [Full Text] [Related]
72. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents. Ranganathan P Curr Opin Mol Ther; 2008 Dec; 10(6):562-7. PubMed ID: 19051134 [TBL] [Abstract][Full Text] [Related]
73. Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Bruce ES; Kearsley-Fleet L; Watson KD; Symmons DP; Hyrich KL Rheumatology (Oxford); 2016 Jul; 55(7):1336-7. PubMed ID: 27118877 [No Abstract] [Full Text] [Related]
74. Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. Smith SL; Plant D; Lee XH; Massey J; Hyrich K; Morgan AW; Wilson AG; Isaacs J; Barton A Pharmacogenomics; 2016 May; 17(7):715-20. PubMed ID: 27180831 [TBL] [Abstract][Full Text] [Related]
75. Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis. Cui J; Diogo D; Stahl EA; Canhao H; Mariette X; Greenberg JD; Okada Y; Pappas DA; Fulton RS; Tak PP; Nurmohamed MT; Lee A; Larson DE; Kurreeman F; Deluca TL; O'Laughlin M; Fronick CC; Fulton LL; Mardis ER; van der Horst-Bruinsma IE; Wolbink GJ; Gregersen PK; Kremer JM; Crusius JB; de Vries N; Huizinga TW; Fonseca JE; Miceli-Richard C; Karlson EW; Coenen MJ; Barton A; Plenge RM; Raychaudhuri S Arthritis Rheumatol; 2017 Apr; 69(4):735-741. PubMed ID: 27788309 [TBL] [Abstract][Full Text] [Related]
76. Drug treatments for rheumatoid arthritis: looking backwards to move forwards. Miossec P BMJ; 2015 Mar; 350():h1192. PubMed ID: 25769296 [No Abstract] [Full Text] [Related]
77. The addition of adalimumab to methotrexate reduces rheumatoid arthritis activity in patients with longstanding disease. Cutolo M Clin Exp Rheumatol; 2004; 22(2):144. PubMed ID: 15083879 [No Abstract] [Full Text] [Related]
78. TNF alpha blockade in rheumatoid arthritis--time for caution or enthusiasm? Hamilton JD; Wilson HE; Madhok R; McInnes IB; Capell HA Scott Med J; 2001 Jun; 46(3):67-70. PubMed ID: 11501322 [No Abstract] [Full Text] [Related]
79. Etanercept: anti-tumor necrosis factor therapy for rheumatoid arthritis. McGahan L Issues Emerg Health Technol; 1999 Oct; (8):1-6. PubMed ID: 11811215 [No Abstract] [Full Text] [Related]
80. Deletion at 2q14.3 is associated with worse response to TNF-α blockers in patients with rheumatoid arthritis. Gu KN; Bang SY; Lee HS; Park Y; Kang JY; Kim JS; Nam B; Yoo HS; Shin JM; Lee YK; Lee TH; Chun S; Cho SK; Choi CB; Sung YK; Kim TH; Jun JB; Yoo DH; Kim K; Bae SC Arthritis Res Ther; 2019 Aug; 21(1):195. PubMed ID: 31462329 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]